CTAD 2019, December 4-7, San Diego

December 2, 2019

Schedule a meeting with Signant Health

LB11 Improving measurement of agitation in dementia incorporating IPA Agitation Working Group definition Zahinoor Ismail (1), Adelaide De Mauleon (2), Jeannie Leoutsakos (3), Cedric O'gorman (4), David Miller (5), Paul Rosenberg (3) Maria Soto Martin (2), Constantine Lyketsos (3) (1) University of Calgary, Canada, (2) Centre Hospitalier Universitaire, France, (3) Johns Hopkins, United States, (4) Axsome, United States, (5) Signant Health, United States

P116 Analysis of the Rates and Types of Errors on Paper Administration of the Neuropsychiatric Inventory Sarah KARAS, Todd FEASTER, Bomi HONG (1) Signant Health, United States
P117 Analysis of the Rates and Types of Errors on the Cohen-Mansfield Agitation Inventory in Agitation in Dementia Clinical Trials H Todd FEASTER, Bomi HONG, Sarah KARAS (1) Signant Health, United States
P122 Comparisons between ADAS-Cog 11 and CDR System measures in the assessment of cognitive dysfunction in mild to moderate Alzheimer’s disease Pascal GOETGHEBEUR (1), Danielle DIGREGORIO (2), Martina MICALETTO (1), Marcella ROY (3), Juha ROURU (4), Keith WESNES (1) (1) Signant Health, United Kingdom, (2) Signant Health, United States, (3) Signant Health, Czech Republic, (4) Signant Health, Finland
P148 Comparing the Standard and Electronic Versions of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale: A Validation Study Diana MICHALCZUK (1), Todd SOLOMON (2, 3), Jordan BARBONE (2), Todd FEASTER (2), David MILLER (2), Guy DEBROS (1), Cynthia MURPHY (1) (1) The Memory Clinic, United States, (2) Signant Health, United States, (3) Boston University School of Medicine, United States
P159 Searching for the best outcome for clinical trials for Agitation symptoms in AD: CMAI vs NPI-C. Results from the A3C study Maria SOTO MARTIN (1), Adelaide DE MAULEON (1), Zahinoor ISMAIL (2), Jeannie Marie LEOUTSAKOS (3), David MILLER (4), Paul ROSENBERG (3), Sandrine ANDRIEU (1), Bruno VELLAS (1), Constantine LYKETSOS (3) (1) Alzheimer Disease Clinical and Research Center. Gerontopole. Toulouse University Hospital, France, (2) Hotchkiss Brain Institute and O'Brien Institute for Public Health. University of Calgary, Canada, (3) Department of Psychiatry and Behavioral Sciences, Johns Hopkins Bayview. Johns Hopkins University, United States, (4) Signant Health United States

Signant's Patient-Centric Technology Suite:

  • Patient Data:  eCOA/ePRO, eCOA/eClinRO, Sensors and Wearables

  • Patient Experience:  eConsent, Patient Engagement

  • Clinical Supplies:  IRT, Forecasting and Planning, Inventory Management

  • Endpoint Quality:  Rater Training and Data Quality Monitoring, Scientific and Clinical Consulting, Data Quality Analytics

About Signant Health 

The best technology succeeds in the background. Signant Health provides solutions that simplify every step of the patient journey to make it easier for people to participate in, and for sites and study teams to run, clinical trials. Signant unites eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite – an evolution built on more than 20 years of proven clinical research technology. Our intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable hundreds of sponsors and CROs (including all Top 20 pharma) to extend the reach of drug development, expand patient opportunities and improve data quality – helping them bring life-changing therapies to our families and communities around the world. 

No Previous Articles

Next Article
eCOA Forum: Dec 10-11, 2019, Philadelphia, PA
eCOA Forum: Dec 10-11, 2019, Philadelphia, PA

eCOA Forum provides opportunities for learning among individuals working in all aspects of clinical data co...


First Name
Last Name
Country (Citizenship)
Product Interest
Opt-In to Future Emails
We will contact you shortly
Error - something went wrong!